International Journal of Molecular Sciences: Immunotherapy in advanced prostate cancer-light at the end of the tunnel?
-
摘要: 在很多实体瘤中免疫治疗已经成为一种标准治疗方案，然而，免疫治疗在前列腺癌中的探索仍未转化为临床实践。前列腺癌高度免疫抑制的"冷"肿瘤微环境降低了很多免疫治疗方案的疗效，包括免疫检查点抑制剂。随着对于肿瘤-免疫系统相互作用了解的深入，研发人员重新看到了未来在前列腺癌中优化免疫治疗策略的希望。本篇综述旨在提供前列腺癌免疫治疗的最新进展及展望未来的发展方向，帮忙医生更好地了解临床前和临床开发中的治疗策略。Abstract: Immunotherapeutic treatment approaches are now an integral part of the treatment of many solid tumors. However, attempts to integrate immunotherapy into the treatment of prostate cancer have been disappointing so far. This is due to a highly immunosuppressive, "cold" tumor microenvironment. The consequence is a reduced efficacy of many established immunotherapeutic treatments such as checkpoint inhibitors. However, a growing understanding of the underlying mechanisms of tumor-immune system interactions raises hopes that immunotherapeutic strategies can be optimized in the future. The aim of this review is to provide an overview of the current status and future directions of immunotherapy development in prostate cancer, and to better understand current therapeutic strategies under preclinical and clinical development.
-
Key words:
- immunotherapy /
- advanced prostate cancer /
- PD-L1 /
- immune checkpoint inhibitors /
- tumor microenvironment
-
-
[1] Alatrash G.Cancer immunotherapies,their safety and toxicity[J].Expert Opin Drug Saf,2013,12(5):631-645. doi: 10.1517/14740338.2013.795944
[2] Topalian SL. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26): 2443-2454. doi: 10.1056/NEJMoa1200690
[3] Basnet A, Khullar G, Mehta R, et al. A case of locally advanced castration-resistant prostate cancer with remarkable response to nivolumab[J]. Clin Genitourin Cancer, 2017, 15(5): e881-e884. doi: 10.1016/j.clgc.2017.05.005
[4] Cabel L, Loir E, Gravis G, et al. Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients[J]. J Immunother Cancer, 2017, 5: 31. doi: 10.1186/s40425-017-0232-7
[5] Abida W, Cheng ML, Armenia J, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade[J]. JAMA Oncol, 2019, 5(4): 471-478. doi: 10.1001/jamaoncol.2018.5801
[6] Hoimes CJ. KEYNOTE-199 cohorts(C)4 and 5: Phase Ⅱ study of pembrolizumab(pembro)plus enzalutamide(enza)for enza-resistant metastatic castration-resistant prostate cancer(mCRPC)[J]. J Clin Oncol, 2020, 38(15_suppl): 5543-5543. doi: 10.1200/JCO.2020.38.15_suppl.5543
[7] Galluzzi L, Buqué A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anticancer agents[J]. Cancer Cell, 2015, 28(6): 690-714. doi: 10.1016/j.ccell.2015.10.012
[8] Fizazi K. CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer[J]. J Clin Oncol, 2021, 39(6_suppl): 12-12. doi: 10.1200/JCO.2021.39.6_suppl.12
[9] Fizazi K, González Mella P, Castellano D, et al. Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase Ⅱ CheckMate 9KD trial[J]. Eur J Cancer, 2022, 160: 61-71. doi: 10.1016/j.ejca.2021.09.043
[10] Strickland KC. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer[J]. Oncotarget, 2016, 7(12): 13587-13598. doi: 10.18632/oncotarget.7277
[11] Pachynski RK. CheckMate 9KD cohort A1 final analysis: Nivolumab(NIVO)+ rucaparib for post-chemotherapy(CT)metastatic castration-resistant prostate cancer(mCRPC)[J]. J Clin Oncol, 2021, 39(15_suppl): 5044-5044. doi: 10.1200/JCO.2021.39.15_suppl.5044
[12] Petrylak DP. 579MO CheckMate 9KD cohort A2 final analysis: Nivolumab(NIVO)+ rucaparib for chemotherapy(CT)-naïve metastatic castration-resistant prostate cancer(mCRPC)[J]. Ann Oncol, 2021, 32: S629-S630. doi: 10.1016/j.annonc.2021.08.1092
[13] Yakes FM. Cabozantinib(XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth[J]. Mol Cancer Ther, 2011, 10(12): 2298-2308. doi: 10.1158/1535-7163.MCT-11-0264
[14] Kwilas AR, Ardiani A, Donahue RN, et al. Dual effects of a targeted small-molecule inhibitor(cabozantinib)on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine[J]. J Transl Med, 2014, 12: 294. doi: 10.1186/s12967-014-0294-y
[15] Tolaney SM, Ziehr DR, Guo H, et al. Phase Ⅱ and biomarker study of cabozantinib in metastatic triple-negative breast cancer patients[J]. Oncologist, 2017, 22(1): 25-32. doi: 10.1634/theoncologist.2016-0229
[16] Agarwal N. LBA24 Cabozantinib(C)in combination with atezolizumab(A)in patients(pts)with metastatic castration-resistant prostate cancer(mCRPC): Results of expanded cohort 6 of the COSMIC-021 study[J]. Ann Oncol, 2021, 32: S1299-S1300.
[17] Sandhu S. PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer(mCRPC)[J]. J Clin Oncol, 2022, 40(16_suppl): 5017-5017. doi: 10.1200/JCO.2022.40.16_suppl.5017
[18] von Amsberg G. Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?[J]. Int J Mol Sci, 2022, 23(5): 111.
[19] Graff JN. Pembrolizumab(pembro)plus enzalutamide(enza)for enza-resistant metastatic castration-resistant prostate cancer(mCRPC): KEYNOTE-199 cohorts 4-5[J]. J Clin Oncol, 2020, 38(6_suppl): 15-15. doi: 10.1200/JCO.2020.38.6_suppl.15
[20] National Comprehensive Cancer Network. Prostate Cancer(Version 4.2022).
[21] Petrylak DP, Ratta R, Gafanov R, et al. KEYNOTE-921: Phase Ⅲ study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer[J]. Future Oncol, 2021, 17(25): 3291-3299. doi: 10.2217/fon-2020-1133
[22] Graff JN. KEYNOTE-641: a Phase Ⅲ study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer[J]. Future Oncol, 2021, 17(23): 3017-3026. doi: 10.2217/fon-2020-1008
[23] Drake CG. A phase Ⅲ, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer(mCRPC; CheckMate 7DX)[J]. Ann Oncol, 2020, 31: S546-S546.
[24] Agarwal N. A Phase Ⅲ, randomized, open-label study(CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer[J]. Future Oncol, 2022, 18(10): 1185-1198. doi: 10.2217/fon-2021-1096
-
计量
- 文章访问数: 889
- PDF下载数: 196
- 施引文献: 0
下载: